Moteur de recherche d’entreprises européennes

Financement de l’UE (5 962 801 €) : Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope Hor01/05/2018 Programme de recherche et d'innovation de l'UE « Horizon »

Vue d’ensemble

Texte

Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope

Prostate Cancer (PCa) is the second leading cause of cancer, among men in Europe. There are currently major unmet needs in this field, such as insufficient knowledge on risk factors that contribute to PCa and on patient characteristics (including genetic profiles) that could facilitate patient stratification. Finally, there is lack of meaningful engagement of all key stakeholders, while the knowledge currently gained from clinical practice and real life data is not being fed back into PCa patients’ care pathways. There is thus a need for better definition of PCa across all stages, improved patient’s stratification at diagnosis, and standardisation of PCa-related outcomes based on real life data. PIONEER’s unique dual approach is to first identify critical evidence gaps in PCa by respected Key Opinion Leaders, and then embark on a research priority setting exercise that reflects the needs of all key stakeholders in PCa management. To achieve this, PIONEER has brought together comprehensive datasets that consists of the most relevant prostate clinical trials and registries, large epidemiological cohorts, electronic heath records, and real-life data from different European (and non-European) patient populations. These unique data sets will be integrated, standardised, harmonised and analysed using approaches that are built on our experience of similar previous IMI projects i.e EMIF, and eTRIKS, and analysed using a unique set of methodologies and advanced analytics methods (OMOP, eHS). PIONEER has already performed a first PCa research priority setting survey, where major stakeholders were asked to identify the current unmet needs in PCa. The five most important open questions will be used as pilot studies to verify PIONEER’s research framework. As such, PIONEER’s deliverables will be outcome-driven, value-based and patient-centric, and relevant to all key stakeholders, as they would have been meaningfully involved from the inception of the project.


Association Eisbm 758 200 €
ASTELLAS PHARMA EUROPE B.V. 0,00 €
Astrazeneca AB 0,00 €
BAYER AG 0,00 €
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM 415 349 €
European Alliance for Personalised Medicine 180 000 €
European Cancer Patient Coalition 69 994 €
European Organisation for Research AND Treatment OF Cancer Aisbl 16 000,00 €
FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG e. V. 125 000 €
Goeteborgs Universitet 150 650 €
HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF e. V. 101 300 €
IHE, Institutet FOR Halso- och Sjukvardsekonomi AB 175 000 €
Imperial College of Science Technology and Medicine 200 000 €
IMS Information Solutions Medical Research Ltd. 0,00 €
International Consortium for Healthoutcomes Measurement Ltd. 31 250 €
Janssen Pharmaceutica N.V. 0,00 €
King's College London 359 000 €
Labcorp Early Development Laboratories Ltd. 0,00 €
Lunds Universitet 185 761 €
NV SAS Institute SA 0,00 €
ORION Oyj 0,00 €
Pinsent Masons LLP 188 800 €
PNO Life Sciences & Health B.V. 237 500 €
Sanofi-Aventis Recherche & Developpement 0,00 €
STICHTING EUROPEAN UROLOGICAL Foundation 797 439 €
STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM 124 922 €
TAMPEREEN KORKEAKOULUSAATIO sr 212 500 €
TECHNISCHE UNIVERSITAET DRESDEN 125 000 €
The Ecancer Global Foundation 37 333 €
THE HYVE B.V. 400 000 €
The University Court of the University of Aberdeen 409 303 €
UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF 150 000 €
Universita Vita-Salute SAN Raffaele 312 500 €
WEIZMANN INSTITUTE OF SCIENCE 200 000 €

https://cordis.europa.eu/project/id/777492

Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.